TERN Share Price Performance
US$52.95
50.05 (1,725.86%)
46.3% undervalued intrinsic discount
US$98.57
Fair Value
Price US$52.95
AverageSven US$98.57
Fair ValueUS$98.57
Share Pricen/a
Terns Pharmaceuticals, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
TERN Community Narratives
AV
Fair Value
·Fair Value US$98.57 46.3% undervalued intrinsic discount
TERN: Positioned for Dominance – The Intrinsic Value of TERN-701 Points to $98.57
1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
TERN: Positioned for Dominance – The Intrinsic Value of TERN-701 Points to $98.57
TERN: Positioned for Dominance – The Intrinsic Value of TERN-701 Points to $98.57 Terns Pharmaceuticals (TERN) is fundamentally undervalued based on the clinical profile of its lead oncology asset, TERN-701. The latest data establish a clear trajectory for market leadership in Chronic Myeloid Leukemia (CML), justifying an intrinsic valuation target of 98.57 per share.Read more
AV
US$98.57
46.3% undervalued intrinsic discount
Fair Value
Profit Margin
15.39%
Future PE
22.83x
Price in 2030
US$0
Trending Discussion
Recently Updated Narratives
AV
TERN: Positioned for Dominance – The Intrinsic Value of TERN-701 Points to $98.57
Fair Value: US$98.57 46.3% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Terns Pharmaceuticals, Inc. Key Details
About TERN
- Founded
- 2016
- Employees
- 59
- CEO
- WebsiteView website
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. As of May 4, 2026, Terns Pharmaceuticals, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
